Please login to the form below

Not currently logged in


This page shows the latest Strimvelis news and features for those working in and with pharma, biotech and healthcare.

GSK hands rare disease assets over to Orchard

GSK hands rare disease assets over to Orchard

At the time, chief executive Emma Walmsley said the rare diseases unit - which chalked up one success with the launch of ex vivo gene therapy Strimvelis for children with adenosine deaminase ... Along with Strimvelis, GSK is passing over two therapies in

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Another EU drug, Strimvelis, targeting immune deficiency, retails for $665, 000.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Two Advanced Therapy Medicinal Products (ATMP), Strimvelis (for the treatment of severe combined immunodeficiency) and Zalmoxis (for the treatment of certain types of high-risk haematological malignancies), were approved in the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...